IPCALAB IPCA Laboratories Q2 FY26 results (Jul–Sep 2025) and concall
Ipca Laboratories reported a strong Q2 FY26, driven by robust domestic formulation growth and significant margin expansion across both standalone and consolidated entities. The API business also performed exceptionally well. While export formulations saw a Q2 decline, H1 remained flat. The company is actively integrating Unichem, focusing on market expansion and R&D, and expects continued margin improvement in the second half of the fiscal year.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q2 FY26: revenue up 8.5%, net profit up 14.2% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|
| Revenue | 2,355 | 2,245 | 2,247 | 2,309 | 2,556 +9% |
| EBITDA | 441 | 463 | 429 | 416 | 545 +24% |
| Net profit | 246 | 276 | 64 | 233 | 281 +14% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
